{
    "2019-07-07": [
        [
            {
                "time": "2023-10-17",
                "original_text": "Better Buy: Pfizer vs. Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Johnson & Johnson",
                        "Better Buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "How private equity overcame its fear of dabbling in drugs",
                "features": {
                    "keywords": [
                        "private equity",
                        "drugs",
                        "overcame fear"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "private equity"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}